Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | CFD | P00746 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6096444 | 0.92 | GAA (0.50) | KMT2AGAAPOLBALDH1A1HPGD | |
| SCHEMBL6098329 | 0.90 | PKM (0.44) | KMT2ACFDGAAPOLBALDH1A1 | |
| SCHEMBL6094041 | 0.87 | LPAR5 (0.45) | KMT2AGAAPOLBALDH1A1HPGD | |
| SCHEMBL6094427 | 0.87 | TSHR (0.44) | KMT2AGAAALDH1A1HPGDLMNA | |
| SCHEMBL6096050 | 0.86 | GAA (0.40) | KMT2AGAAPOLBALDH1A1HPGD | |
| SCHEMBL6095940 | 0.86 | NPC1 (0.41) | KMT2AGAAPOLBALDH1A1HPGD | |
| SCHEMBL6095437 | 0.86 | SCN9A (0.48) | KMT2AALDH1A1HPGDLMNAMAPT | |
| SCHEMBL6094865 | 0.85 | ALDH1A1 (0.42) | KMT2AGAAPOLBALDH1A1HPGD | |
| SCHEMBL6095989 | 0.84 | GAA (0.39) | KMT2AGAAPOLBALDH1A1HPGD | |
| SCHEMBL6094905 | 0.83 | SCN9A (0.42) | KMT2AGAAALDH1A1HPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7064124-B2 | NF-κB inhibitor containing substituted benzoic acid derivative as active ingredient | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2006-06-20 | — | — | US | claimed |
| US-7064124-B2 | NF-κB inhibitor containing substituted benzoic acid derivative as active ingredient | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2006-06-20 | — | — | US | disclosed |
| US-20040122244-A1 | Nf-kappa b inhibitor containing substituted benzoic acid derivative as active ingredient | DAIICHI ASUBIO PHARMA CO., LTD. (JP) | 2004-06-24 | — | — | US | disclosed |
| EP-1314712-A1 | NF-KAPPA-B INHIBITOR CONTAINING SUBSTITUTED BENZOIC ACID DERIVATIVE AS ACTIVE INGREDIENT | Daiichi Suntory Pharma Co., Ltd. (JP) | 2003-05-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122244-A1 | Nf-kappa b inhibitor containing substituted benzoic acid derivative as active ingredient | NFKBIA, NFKB1, IKBKB | KMT2A 2280/4885CFD 2791/4885GAA 781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.